Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (101-110 of 162) with videos related to

Pageof 17
Sort By:
Haematologica|December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibDeborah L White, Jerald Radich, Simona Soverini, et al.
Blood|February 13, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyFausto Castagnetti, Francesca Palandri, Marilina Amabile, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP reportGiovanni Martinelli, Ilaria Iacobucci, Clelia Tiziana Storlazzi, et al.
American Journal of Hematology|June 5, 2025
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network DatabaseFabio Stagno, Rosalba Cucci, Giovanni Marsili, et al.
Haematologica|January 4, 2011
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosisSimona Soverini, Antonella Vitale, Angela Poerio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemiaSimona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Haematologica|March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Pageof 17

Showing results (101-110 of 162) with videos related to

Sort By:
Pageof 17
Haematologica|December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibDeborah L White, Jerald Radich, Simona Soverini, et al.
Blood|February 13, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyFausto Castagnetti, Francesca Palandri, Marilina Amabile, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid LeukemiaSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2006
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patientsIlaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti, et al.
Blood|July 11, 2009
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSimona Soverini, Alessandra Gnani, Sabrina Colarossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP reportGiovanni Martinelli, Ilaria Iacobucci, Clelia Tiziana Storlazzi, et al.
American Journal of Hematology|June 5, 2025
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network DatabaseFabio Stagno, Rosalba Cucci, Giovanni Marsili, et al.
Haematologica|January 4, 2011
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosisSimona Soverini, Antonella Vitale, Angela Poerio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemiaSimona Soverini, Giovanni Martinelli, Sabrina Colarossi, et al.
Haematologica|March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Pageof 17